Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan

Journal of Gastroenterology

Volumn 47, Issue 7, 2012, Pages 814-822

  Suzuki, Fumitaka ^a   Arase, Yasuji ^a   Suzuki, Yoshiyuki ^a   Akuta, Norio ^a   Sezaki, Hitomi ^a   Seko, Yuya ^a   Kawamura, Yusuke ^a   Hosaka, Tetsuya ^a   Kobayashi, Masahiro ^a   Saito, Satoshi ^a   Ikeda, Kenji ^a   Kobayashi, Mariko ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Chronic hepatitis B; Genotype; Hepatitis B surface antigen; Hepatitis B virus; Interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA INTERFERON; BETA INTERFERON; HEPATITIS B(E) ANTIGEN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VIRUS DNA;

ADOLESCENT; AGE; AGED; ARTICLE; DATA ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; GENDER; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL CLEARANCE; VIRUS LOAD;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; JAPAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865041484     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0548-5     Document Type: Article

References (31)

1. Beasley RP, Hwang LW, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet. 1981;2:1129-233.
2. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995;333:1657-61.
3. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-16.
4. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAgpositive chronic hepatitis B. N Engl J Med. 2006;354:1001-10.
5. Lok ASF, Heathcote EJ, Hoofnagel JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology. 2001;120:1828-53.
6. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-31.
7. van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, et al. Long-term follow-up of alphainterferon treatment of patients with chronic hepatitis B. Hepatology. 2004;39:804-10.
8. Wong DHK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med. 1993;119:312-23.
9. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? Hepatology. 1989;10:761-3.
10. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisolone withdrawal for the treatment of chronic hepatitis B. N Engl J Med. 1990;323:295-301.
11. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002;36:186-94.
12. Yang YF, Zhao W, Xia HM, Zhong YD, Huang P, Wen J. Longterm efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis. Antiviral Res. 2010;85:361-5.
13. Suzuki F, Arase Y, Akuta N, Tsubota A, Suzuki Y, Sezaki H, et al. Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan. J Gastroenterol. 2004;39:969-74.
14. Arase Y, Chayama K, Tsubota A, Murashima N, Suzuki Y, Koida I, et al. A randomized, double-blind, controlled trial of natural interferon-a therapy for e-antigen-negative chronic hepatitis B patients with abnormal transaminase levels. J Gastroenterol. 1996;31:559-64.
15. Arase Y, Tsubota A, Saitoh S, Suzuki Y, Kobayashi M, Suzuki F, et al. Randomized, controlled trial of natural interferon-a therapy for e-antigen-positive chronic hepatitis B patients. Hepatol Res. 2002;23:98-104.
16. Usuda S, Okamoto H, Imawari H, Baba K, Tsuda F, Miyakawa Y, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in preS2-region product. J Virol Method. 1999;80:97-112.
17. Tadokoro K, Kobayashi M, Yamaguchi T, Suzuki F, Miyauchi S, Egashira T, et al. Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes. J Virol Method. 2006;138:30-9.
18. Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, et al. Clinical characteristics of patients infected with hepatitis B virus genotypes A, B and C. J Gastroenterol. 2002;37:35-9.
19. Niderau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J M. 1996;334:1422-7.
20. Lin SM, Yu KL, Lee CM, Chien RN, Sheen IS, Chu CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007;46:45-52.
21. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-a treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2001;34:306-13.
22. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol. 2002;36:263-70.
23. Lampertico P, Ninno ED, Vigano M, Romeo R, Donato MF, Sablon E, et al. Long-term suppression of hepatitis B e antigennegative chronic hepatitis B by 24-month interferon therapy. Hepatology. 2003;37:756-63.
24. Lau DTY, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology. 1997;113:1660-7.
25. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol. 2000;33:998-1002.
26. Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment of HBeAg negative/ serum HBV DNA positive chronic active hepatitis B. J Hepatol. 1990;11:S133-6.
27. Pastore G, Santantonio T, Milella A, Monno L, Mariano N, Moschetta R, et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in serum: response to a 6-month course of lymphoblastoid interferon. J Hepatol. 1992;20:221-5.
28. Fattovich G, Farci P, Rugge M, Brollo G, Mandas A, Pontisso P, et al. A randomized, controlled trial of lymphoblastoid interferonalfa in patients with chronic hepatitis B lacking HBeAg. Hepatology. 1992;15:584-9.
29. Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology. 1997;26:1621-5.
30. Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med. 2006;119:71 e9-e16.
31. Kobayashi M, Suzuki F, Akuta N, Hosaka T, Sezaki H, Yatsuji H, et al. Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine. J Med Virol. 2007;79:1472-7.